• Recruiting

NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma

Updated: Sep 30


NCT03374085: Phase 1/2: CC-92480 Monotherapy and with Dex in Relapsed / Refractory Multiple Myeloma

CC-92480 MEZI CELMOD MYELOMA TRIAL

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)


This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM).


RRMM patient previously treated with at least 3 prior regimens including lenalidomide or pomalidomide, a proteasome inhibitor and a CD38 antibody will be eligible.


Sponsor

Celgene


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT03374085


Official Title: A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

First Posted : December 15, 2017

Click here for details on ClinicalTrials.gov

 

NCI Drug Dictionary info on cereblon E3 ubiquitin ligase modulating agent CC-92480

CC-92480

 

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

2020 ASCO Annual Meeting

Abstract 8500

https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.8500

 

* cereblon E3 ubiquitin ligase modulating agent CC-92480

* CELMoD CC-92480

* Drug: CC-92480

* Drug: Dexamethasone (Decadron)

 

- California: City of Hope Duarte

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Georgia: Emory University Atlanta

- Massachusetts: Dana-Farber Cancer Institute/Harvard Cancer Center Boston

- New York: Roswell Park Cancer Institute Buffalo

- New York: Memorial Sloan-Kettering Cancer Center New York

- Tennessee: Sarah Cannon Research Institute Nashville

- Texas: The University of Texas MD Anderson Cancer Center Houston

 

Locations

United States, California

United States, Colorado

United States, Georgia

United States, Massachusetts

United States, New York

United States, South Carolina

United States, Tennessee

United States, Texas

United States, Virginia

United States, Washington

Canada

Canada, Alberta

Canada, Ontario

Canada, Quebec

Australia, New South Wales

Australia, South Australia

Australia, Victoria

Europe

United Kingdom

Denmark

Spain

Finland

Belgium

Asia

Japan

Korea, Republic of

 

RELATED POSTS

NCT05552976: Phase 3: (SUCCESSOR-2) CC-92480 + Carfilzomib-dex (480Kd) Vs Carfilzomib-dex (Kd) RRMM

Click here for details


NCT05519085: Phase 3: (SUCCESSOR-1) CC-92480 + Bortezomib-dex (480Vd) Vs Pom-Bortzomib-dex (PVd) RRMM

Click here for details


NCT05372354: Phase 1/2: CC-92480 (BMS-986348) in Combination With Other Treatments in RRMM Myeloma

Click here for details


NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002

Click here for details


MEZI MYELOMA


Posts Archive